Tina Kim-Hafken has over 18 years of regulatory affairs experience in oncology and chemistry, manufacturing and controls (CMC) with a strong track record of leading global marketing and clinical trial applications, negotiating innovative strategies and delivering regulatory approvals. Prior to joining Rain, Tina was senior director of regulatory affairs and regulatory science at Seagen Inc., where she successfully led the submission and approval of TUKYSA® (tucatinib) for metastatic HER2-postive breast cancer and was responsible for developing effective global regulatory strategies. Before Seagen Inc., she was senior manager of global regulatory & safety and CMC at Amgen Inc., where she established global CMC development and post approval strategies for late stage and commercial products. Tina graduated with an MS in biotechnology from Johns Hopkins University and received her BA in chemistry and BA in music from the University of Kansas.